Characterization of Genome Integrity for Oversized Recombinant AAV Vector

被引:176
作者
Dong, Biao
Nakai, Hiroyuki [2 ]
Xiao, Weidong [1 ]
机构
[1] Temple Univ, Sol Sherry Thrombosis Res Ctr, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA
[2] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Philadelphia, PA USA
基金
美国国家卫生研究院;
关键词
ADENOASSOCIATED VIRAL VECTORS; GENE-THERAPY VECTORS; PACKAGING CAPACITY; HEMOPHILIA-A; HEAVY-CHAIN; MOUSE-LIVER; HIGH-TITER; DNA-PKCS; IN-VIVO; VIRUS;
D O I
10.1038/mt.2009.258
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Application of recombinant adeno-associated virus (rAAV) in gene therapy has been limited by its packaging capacity. Recent studies suggested that rAAV could achieve persistent transgene expression beyond 4.7-kb packaging limit. To clarify the mechanism leading to transgene expression from oversized rAAV vector, we constructed a series of rAAV vectors with genomes ranging from 2.9 to 7.2 kb. A plasmid replication origin and an ampicillin-resistant marker were included in the vector to facilitate the recovery of circularized, post-transduction AAV genome. Southern dot-blot analysis and silver staining confirmed that rAAVs could be produced at varying vector size. However, the vector yields decreased approximately tenfold for oversized vectors as compared to regular ones. Alkaline Southern blot hybridization suggested that the packaged genomes for oversized vectors were truncated. In the cells transduced by the above vectors, circularized rAAV monomers could be rescued at 24 hours after infection. Few recovered AAV genomes were >5 kb regardless of the initial vector size. In mice receiving the above vectors, larger circularized rAAV genomes could be recovered for oversized vectors at day 21 after vector administration. Our studies suggested that the partially packaged rAAV sequences may complement each other to restore full expression cassette.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 38 条
[31]   Pathways of removal of free DNA vector ends in normal and DNA-PKcs-deficient SCID mouse Hepatocytes transduced with rAAV vectors [J].
Nakai, H ;
Storm, TA ;
Fuess, S ;
Kay, MA .
HUMAN GENE THERAPY, 2003, 14 (09) :871-881
[32]   Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo [J].
Nakai, H ;
Yant, SR ;
Storm, TA ;
Fuess, S ;
Meuse, L ;
Kay, MA .
JOURNAL OF VIROLOGY, 2001, 75 (15) :6969-6976
[33]   Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver [J].
Nakai, H ;
Iwaki, Y ;
Kay, MA ;
Couto, LB .
JOURNAL OF VIROLOGY, 1999, 73 (07) :5438-5447
[34]   Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D [J].
Rodino-Klapac, L. R. ;
Lee, J. -S. ;
Mulligan, R. C. ;
Clark, K. R. ;
Mendell, J. R. .
NEUROLOGY, 2008, 71 (04) :240-247
[35]  
Samulski RJ, 2003, E SCHERING RES FDN W, V43, P25
[36]   RESCUE OF ADENO-ASSOCIATED VIRUS FROM RECOMBINANT PLASMIDS - GENE CORRECTION WITHIN THE TERMINAL REPEATS OF AAV [J].
SAMULSKI, RJ ;
SRIVASTAVA, A ;
BERNS, KI ;
MUZYCZKA, N .
CELL, 1983, 33 (01) :135-143
[37]   Self-complementary recombinant adeno-associated viral vectors: Packaging capacity and the role of rep proteins in vector purity [J].
Wu, Jianqing ;
Zhao, Weihong ;
Zhong, Li ;
Han, Zongchao ;
Li, Baozheng ;
Ma, Wenqin ;
Weigel-Kelley, Kirsten A. ;
Warrington, Kenneth H., Jr. ;
Srivastava, Arun .
HUMAN GENE THERAPY, 2007, 18 (02) :171-182
[38]   Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro [J].
Yang, CC ;
Xiao, X ;
Zhu, X ;
Ansardi, DC ;
Epstein, ND ;
Frey, MR ;
Matera, AG ;
Samulski, RJ .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9231-9247